Drugs that contain Asciminib Hydrochloride
1. Drug name - SCEMBLIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
May, 2033
(10 years from now) | |
| CN104302638B | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| CN104302638A | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| CN104302634A | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| CN104302634B | NOVARTIS | For Inhibiting Activity Of Abl1, Abl2, And Bcr-Abl1 Of Benzamide Derivatives |
May, 2033
(10 years from now) | |
| EP2861576A1 | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| EP2861579B9 | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| EP2861576B1 | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| EP2861579A1 | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
| EP2861579B1 | NOVARTIS | Benzamide Derivatives For Inhibiting The Activity Of Abl1, Abl2 And Bcr-Abl1 |
May, 2033
(10 years from now) | |
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 40MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.